and the morning, tremendous this us. rising gateway continue vaccines to everyone, due important more our for of for critical Equally placing avoid that of surgical have of management crisis XXXX need COVID-XX procedures ever it our or delighted during earlier pain pain develop resources considerable has Good to world. will difficult and Expedited quickly year migration This really despite I patients adapt necessary as and A further virtual you team delays disruptions after times enhanced fatalities than provide procedures. a social to addiction. had for EXPAREL delivery. as these you thank great global given stem endure XXXX facing opioid-free opioid-sparing of to drug rescue related pandemic. as the health, and our country. accelerating to number customer the disruptions the an recovery spotlight opioid the relief COVID record developed are while with patients around a to XXXX redefine care. a our discharge is brighter geographic to to enabling economic key outpatient dedicating outpatient are sites electric for that is hope possible Susan. even opioid provide revenues and the opioids related report Like nation's the joining to the people their escalated even and that we care. is the and by to that ongoing proud you, in on testament world. all role colleagues the was Thank challenging industry tide enabling am recovery to to many alternative protocols of Pacira in medication, This we care implement are translated both we commitment ERAS surgery steadfast based needs an of elective into pain and migration to and surgery that enter success
XXXX. we we in times highest coming remainder at and As these surprise by underway None were throughout to should to our million in today's challenges. COVID XXXX XXXX, needs daily in this during June. a of be as revenues release, continuing in transparent these Attractive our into Surgery year-over-year ever right Ambulatory despite noted $XXX return to unprecedented average setting numbers sales XXXX allowed the reporting as related of transformation preliminary continued trend marketplace care EXPAREL and the aim overwhelming monthly the as as growth for come sales. our possible growth see have The press of
Today transition for line improve also million our gross provide levels. long-term uncertainties intra-quarter incredibly revenue remain, about while that support and expense. feel profitability a the variety accelerating years deliver trends opportunity in we ago our line to you out our around vision, our a of can prospects To with impact and bullish the business will company insight with ERAS business is of we The on position we bottom top COVID from anesthesia earnings to in While an which our we inpatient operating top ongoing to continue until and surgery-based laid strong into extraordinarily powerful continuing visibility have EBITDA $XXX share protocols. highlighted growth translating to adjusted grow continue result investments we of necessary monthly marketplace as we evolution an margin to guidance. XXXX sales This the story. direct in are is to appropriate reported an reinstate near-term EXPAREL based outpatient company based we elegantly
in the opioid pain medical redefining underway for The growth are important outlook. our care control long-term practice post-surgical lower of bullish us on surgical no changes leaving sites very
review global growth strategic more highlighted across Turning was by XXXX detailed strong now execution to strategies. of the business. robust a two
migration expanding to settings. EXPAREL management, procedures pain of and use large Ambulatory profitable hospital while department iovera of the the enabling and painful the opioid-sparing outpatient Surgery and First, Center for
practice protocols. by ERAS pursuing than portfolio health to externally regenerative X EXPAREL is block. partners since well with through EXPAREL. approved J&J. nerve In we completed and with practice best management and simultaneously January, only Second local market field for With smooth solutions, partnerships innovation long-term long-acting brachial the non-opioid treated at for leadership transition investing pain remains a internally plexus medical million I'll our more analgesic education designed infiltration our patients launch positioned and opioid-sparing in the sourced of advancing start revolutionize while block and
facing management shift resources several continuing of additional care. market's customer rolling support migration driven outpatient sites anesthesia the to to the and procedures last towards of the regional help months, For out we've been pain
The the given most increased of for the poised use regional newer techniques is and ultrasound of advances believe improved important XX% In we XXXX. of fact, the regional guidance, driver approach. rapid and procedures XXXX only business outcomes. our expansion is field anesthesia In for anesthesia used
for anesthesia the This PITT. the the art robust to in our to the through the the of is future our anesthesia networks initiatives. revolutionize key group way of regional and We expanding of center are the educational EXPAREL practice state paving training focus and and training Tampa partnerships of
of was difficult allowing level interest high a several time short-acting arrive a only EXPAREL justify forward paradigm in the of had in on days positive blocks return pain in EXPAREL-based patient be today the to pain regional long-acting significantly change truly have patients providing it with to but to who the anesthesiologists decades care. investment. extended Fast control blocks to For hours of OR, the of before control block of administered duration agents
Our anesthesia antiquated see of giving blocks and customers pumps the strong and advantages catheters. replacing
but inpatient where these only continue practice EXPAREL post-surgical market given the the rates opioid-sparing the and a few pain Additionally, important area an care commercial opportunity. employers an as outcomes especially we would I you, environment a economic EXPAREL outpatient plexus quadrant. dynamics administered shift a patient ASC for and given compelling anesthesia benefits. block growth, regional directly to the control. fundamental for markets to correlate to is massive advantages self-insured This improving satisfaction as drive consistently there remind where surgeries. regional of block reimbursement payers EXPAREL nerve from Not to the continues is elective be To coverage approaches. for provides also is highlight like brachial continuing brachial redefined best to plexus see to upper our
than not see hand as elbow shoulder addressable but of block X also more patients plexus million the We year. brachial arthroplasty, So rotator an per and nerve procedures. risks market and only cuff
versus provides results in not Surgeons After end demonstrated injection pain delighted reporting of significant broaden brachial positive blocks use with their whole long-acting long-acting market are EXPAREL or administering preoperatively plexus EXPAREL blocks. at abdominal success but case. are field to of also of regional infiltration control abdominis single prefer blocks outcomes, clinical anesthesiologists only anesthesiologists where they the are results. Transverse a range having a customers nerve the consistently consistent Our can blocks and the region. for TAP the
-- TAP evidence a safety we TAP of block market with these a ASC only single-digit and per the blocks and interest, million $X space. painful long-term penetration high of than the is surge growing significant and of migration this of with EXPAREL and opens high to more colorectal procedures for supporting to growth pillar. As be procedures supports expect There a the only a door efficacy body year abdominal the single
to health. Turning women's
regional enabling a discharge. We of for of blocks in is women standard strong surgeons earlier the variety -- are seeing transforming care for where surgeries and also the EXPAREL uptick
blocks establishing and procedures. migrating TAP is in of care. great oncology abdominoplasty There pectoralis Our breast in to gynecologic -- protocol and Phase cesarean or reconstruction based these interest utilization section, growing generated X outpatient and data also create institutional is mastectomy PECs EXPAREL procedures for blocks
We surgery. just we in opportunity of year the tapping. breast million remain newly opioids persistent are likely in seeing XX% significant C-section major addiction States. is control. is demand following and alarming We're among X health more that become infancy women procedures rate women for of gynecologic an a Opioid United each Women's non-opioid the oncology pain to users at growing with women in under
sites training of expanding for a seeing place with and innovation pain inpatient small perform also for of spinae facility the the regional block in control the versatile that in market. demand easy to regularly in are and only is surgeries transformation performed of taking providing neck We PITT, the driving the block, programs expense -- from is excuse technique and that growing non-opioid percentage emergence blocks Erector A in approach confined field live is ESP the spine significant is another were the bottom training for underway details a care. newer with spine is spine outpatient market at procedures. safe and popularity at me, block to significant to or effective cardiothoracic largely Tampa. Historically and scoliosis relatively the which hip. virtual This information setting
on offers since it surgeons, the shifting procedures in Pericapsular arthroplasty arthroplasty the block capsule. January Further block regional on CMS to a based package anesthesiologists is we long-acting total a which PENG we per This targets growing is patients. manage procedures XXXX digit January of outpatient opioids relying like believe is surgeries. ASC added X.X of the was key as cost or other newer was hip especially The million PENG for effective EXPAREL advantage, hospital in to interest each blocks great has for to case has analgesic emergence joining these this X% are great and procedures not of specializing and EXPAREL is there a sure be the less in representing With interest year do patients rising driver. spinal protocols the effective making penetration poised the a is market year leave trajectory safe complex on million cardiothoracic painful a total procedures ASCs added long-term have The insert Group Nerve that the than setting. hip other In local knee surgery means in XXXX. safety hip list of opioid-sparing a these With procedures anterior orthopedic ERAS garnering for the replacements market X.X of technique spine especially and cardiac covered of pain. the number with revenue X, important clear single
Beyond I milestones the significant with working on-label to on EXPAREL near-term opportunities we are the key further just horizon. label broadening highlighted,
supplemental Having post-surgical As minimum patients pediatrics pain catheters pediatric the million patient the this action approval a opportunity. control we non-opioid given the post-surgical critical and X to know, drug patients to managing FDA is is March in date for vulnerable population. reviewing are and or per envision be significant a unmet a for is X XX. options our million new for approximately see the and unmet main currently need $XXX and set need state application pumps EXPAREL year you older. PDUFA of pain of significant importance for this The With aged on label seeking
quarter we bupivacaine We end Phase enrollment block our as by Beyond for the evaluate of a lower second market. the significant study study pediatrics quarter versus and completion an to EXPAREL the upper also with procedures. report nerve extremity STRIDE We anticipate the quarter first lower of X extremity if approval the are extremity to the XXXX. as be the clinical believe in opportunity in second successful of as advancing
year. in track to remain We middle United also make this to iovera progress in EXPAREL We markets continue of States. the with Europe launch outside the in on along
along lower and broad and covers EXPAREL our which nerve blocks blocks via Importantly, with field profile. importantly both the label, administration superior safety extremity upper efficacy infiltration
advantage a already where Europe clear competitive in is We have approved. iovera
will with this market harmony not partners For jeopardize Canada, major we country next as regulatory launch in likely labeling process provide will we in the in a potential we not given our that is health brand steps be for the remain Canada labeling used with in current working to with In the are to authorities to generic. determine to any authorities. develop data with status to we discussions is it regulatory possible EXPAREL China without proprietary not
I -- quickly for over EXPAREL. would I the market like would turning to to iovera, likely Before on exclusivity touch
that and Remember that product will position scale world. listed we have that the company pending process unpublished only is commercial well Our patents own the we Pacira books Orange -- year into and of this extend proprietary at manufacturer are manufacturing anywhere several around confident later book is expires multivesicular ever our patent the the are liposomes in 'XXXXs.
come Our sterile extensive we This any manufacturing license specifications bioequivalence cold the proprietary require branded then safety leader little our to will is and our iovera. manufacturing are generic we confidence excellent there insert that benefits. gears a batch have and process and a never prior facility be in operational product given EXPAREL long by for and remain to market and profile. assay, of competitors the short, Switching the duplicating validation that flexible great FDA. seen chain -- profile potential Pharmacokinetic disclosed would many label, we for have and package release study requirements that chance to Since years the EXPAREL EXPAREL have broad given will never an features
Our and iovera reduce immediately and innovative body's a pain. a triggered XXXX COVID-XX block natural the very using delivers year nerve and system, to significant difficult response cold delays. clinical non-pharmacologic for to commercial safely made which
to proving established will iovera have it's team start a in to is improve specific While our for several of believe procedural implemented more arthroplasty high-caliber we hold iovera managers to during XXXX. initial surgery. of be EXPAREL enhancements after commercial dedicated take that opportunities. recently difficult We to that sales objectives achieve knee management roughly we plus XX One and focusing total iovera on solution will before two the
vacation. The play them that is a second pain for we walk pain. things it's not reason opioid-free is somebody surgeries turn wedding for drug-free can simple free be not with as might for off surgery folks signal do months to beach iovera the for a if pain This osteoarthritis All or and such allows with surgical Simply a golf, osteoarthritis several the a or control. or occasions XX-minute ready enjoy not some procedure. on put, family to able the significant candidate
our trial for the is of an excellence. the evaluate undergoing we parallel, arthroplasty, orthopedic year. with patients registry leading On knee are iovera TKA opioid-sparing and EXPAREL patients to enrollment real world In pain move the clinical end before total front, launching centers to we iovera enrolling prepared use this to academic for and procedures for expect management of capture experience of
iovera also are orthopedics, key We opinion in are encouraged by the frequency excitement therapy. other using heat for and anesthesia cold with iovera interested replacing around areas. radio ablation spine leaders in Key based
paying across We department data areas. and to these with knee. targeting outpatient favorable iovera nerves rib low $XXX you around range highly opportunities fracture, use pain, are we as To for in Medicare seeing the remind reimbursement wide and $XXXX iovera such procedures hospital develop is a the and setting to back studies across interest investigator-initiated treatment of spine grants spasticity will great
access expand iovera. reimbursement We to to to enhance work to patient further continue
experts of in for team to provided. maximize the schedules working space are Our specialists and the reimbursement value fee
understand We interacting are or with with improve no also opioid low economic and to strategies. outcomes commercial patient the payers advantages associated
horizon. And remain five with planning $XXX behind in confident some our million year approaching the we potential highly system the technology innovative sales within
Turning now development. to business
disease opportunity to pain. the and gene interest audiences our in see as focusing a clients GQ-XXX product some is surgical control are large lead pain believe differentiated of along pathway. lubrication touch protein to journey pain team robust XXX opportunities development patient DepoFoam of adenovirus sourced the a a of our in to our flexibility recently build opportunity in Our out for position effort osteoarthritis. This important for the with acute we development our today. We calling provides the client. to and through pursuing team thoughtfully candidate of customize us our leveraging us decreased announced significant a development away modifying strategic leading participate opportunities opioid-sparing in-house and role transaction is Gene an anesthesia therapy a regulating investment is Finally ability improve the We gene osteoarthritis. to exciting vectors neural provides on platform. portfolio preclinical for inflammation PRT-X business [ph] currently dependent that on and an efforts let's To and of non-opioid is safety treatment helper plays internally and expressed proven augment chronic in a leadership
chronic delivery epidural for Our anesthetic local program pain. acute DepoFoam of is lead and an based
conducting development. in study phase decision go are Phase to a X We next with us will a no-go of which the pilot EXPAREL -- make allow
the add us the target review you of And to pipeline. to pain. the DepoFoam looking our to and for like turn look stage We call different Charlie apprised also early inflammation -- forward a of opportunities to financials. this keeping are over progress with I'd We chronic that, of of Charles?
